Cipla's chief executive Subhanu Saxena is leaving the India-based generics maker at the end of this month amid a shake-up in the company's operations…

Allergan is doubling down in New Jersey by consolidating four of its locations in one big, new U.S. headquarters--and plans to create 300 new jobs along the…

Valeant’s management is assuring investors that the company is well on its way to stabilizing. But now, it's facing what could be its most serious…

A new trend could change pharma's feelings about copay programs: discount offers for generic drugs and biosimilars.

GlaxoSmithKline has struck a money-back guarantee on its gene therapy Strimvelis. The once-and-done treatment for “bubble boy” disease, only the second of its…

Two years after threatening to sue AbbVie for abandoning its $55 billion Shire buyout, hedge fund Elliott Management finally did.

It didn’t take long for AbbVie to strike out against Amgen’s Humira biosimilar. Less than a month after an FDA panel gave the Humira copy a hearty thumbs-up,…

Merck & Co.’s Keytruda saw its fortunes rise significantly Friday, and not just because its Bristol-Myers Squibb rival failed a key lung cancer study.…